Shai Shai Meretzki, PhD - Chief Executive Officer and President
Former founder, CEO and CTO of Pluristem Therapeutics Inc. (OTCBB: PSTI) a cell therapy company, Dr. Meretzki brings broad technical and managerial experience in the biotechnology discipline. Dr. Meretzki has vast experience in biological and chemical R&D, specifically in the area of cell culture, ex-vivo tissue engineering and bone regeneration.He holds PhD and MSc degrees in Biotechnology from the Technion - Israel Institute of Technology in cooperation with the Weizmann Institute, Israel. He also serves as Chairman of the Board at Biological Industries Israel Beit HaEmek Ltd.
YosRoneni Yossi Rauch, MBA - Chairman of the Board
Mr. Rauch served as Chief Economist and Manager of the Economics Department of Leumi PIA, Israel’s largest mutual fund company. He was also Manager of the Treasury Department of Koor-Trade, a group of international trade companies. Mr. Rauch holds an MBA in Finance & Accounting and Computers & Information Systems from Tel Aviv University, and a BA in Economics and Business Administration from Bar-Ilan University.


Yoni Livne, CPA – Chief Financial Officer
Mr. Livne has been serving as Chief Financial Officer since 2014. Before joining Bonus BioGroup, Mr. Livne was Chief Financial Officer at Bee Contact Communication Ltd., a publicly traded company (TASE), and Chief Controller at Dexcel Pharma, a privately held international pharmaceutical company. Mr. Livne holds an MBA in Finance and a BA in Accounting and Economics from The Hebrew University.
1S1A1464 gray

Nir Shtayer, DVM, EMBA - Head of Regulatory Affairs
Dr. Shtayer has over 20 years of experience in the pharmaceutical, biotechnological and medical device industries, with regulatory managerial experience. Prior to joining Bonus BioGroup, Dr. Shtayer was the Regulatory Affairs Manager at PolyPid and Teva Pharmaceutical as well as the Regulatory Affairs Manager for early development programs at Omrix (Johnson & Johnson).  Dr. Shtayer brings a comprehensive understanding of GLP, GMP and GCP regulations, and has vast global experience (FDA, EMA, the Israeli Ministry of Health, ROW) in Regulatory Affairs activities throughout whole life cycle of the products, from research and development to post marketing approval. He holds  a B.A (Animal Science) and DVM (Doctor of Veterinary Medicine) from the Hebrew University, Jerusalem as well as an Executive MBA from UTS, The University of Technology of Sydney, Australia.




AvinoamKadouri In Memory of Avinoam Kadouri

The Bonus BioGroup family is mourning the loss of Prof. Avinoam Kadouri - Founder and Chief Technology Officer. Prof. Kadouri died unexpectedly in September 2016. He was a world-renowned and widely respected leader of industrial biotechnology and process development. Before joining Bonus BioGroup he served as Director at Serono International and Chairman of both ACTIP (Animal Cell Technology Industrial Platform) and the European Association for Bio-Industries. A central yet gentle man, his passing was received with great sadness by everyone in Bonus BioGroup. His deep commitment to the Company and his many contributions towards its establishment, early development and continued progress were insightful and valuable. He was a remarkable colleague and a dear friend. May he rest in peace.